Research programme: NSAIDs transdermal - Acrux

Drug Profile

Research programme: NSAIDs transdermal - Acrux

Alternative Names: NSAID Metered Dose Transdermal System; NSAID transdermal system - Acrux; NSAIDs - Acrux; NSAIDs MDTS®; Topical NSAIDs - Acrux

Latest Information Update: 27 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acrux
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Inflammation; Pain

Highest Development Phases

  • Preclinical Inflammation; Pain

Most Recent Events

  • 27 Sep 2010 The transdermal non-steroidal anti-inflammatory drugs programme of Acrux is still available for licensing.
  • 24 Sep 2010 Formulation development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top